$TMDX

Gunderson Thomas J. sold $722K of TMDX

Gunderson Thomas J. sold 9,624 shares of TransMedics Group, Inc. (TMDX) at $75.06 ($0.72M total) on 2026-06-15.

Original reporting
SEC EDGAR · Gunderson Thomas J.
Published Jun 17, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:29 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$TMDX
Neutral
high confidence
Mentioned
$TMDX
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TMDXNeutralLow
01

Why it matters

The disclosed event is an open-market sale by a director, which can influence short-term sentiment but does not provide new information about TransMedics’ business, financial results, or outlook.

02

Market read

Traders may note insider selling as a sentiment datapoint, but the filing lacks any fundamental catalyst.

03

What to watch

The article does not state whether the director’s remaining stake is meaningful relative to prior holdings, nor does it provide any company performance or guidance changes.

Relevance 5/10Novelty 3/10Timing: filed 2026-06-17, transaction dated 2026-06-15

Background

The article is a SEC Form 4 insider transaction disclosure for TransMedics Group, Inc. (TMDX).

Company-level read

Ticker impact

$TMDXNeutralHigh confidence
Context

TransMedics director Thomas J. Gunderson filed a Form 4 selling 9,624 shares at $75.06 for about $722K, reducing direct holdings to 16,642.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a routine insider transaction with no 10b5-1 plan and no accompanying corporate news, guidance, or operational catalyst in the text.

Market effects

Minimal. Insider selling in a single name does not imply sector-wide changes based on the provided text.

None indicated.

None indicated.

Counterpoint

The sale could be for diversification, taxes, or pre-planned liquidity needs; without additional context, it may not signal reduced confidence.

Key entities

  • TransMedics Group, Inc.

    Company whose director insider sale is disclosed via SEC Form 4.

  • Thomas J. Gunderson

    Director who sold 9,624 shares at $75.06 on 2026-06-15.

Related articles

$TMDXMed

Why TransMedics Stock Is Sinking Today

TransMedics (NASDAQ: TMDX) shares fell about 8% after its Q2 results. The company reported 21% sales growth, but adjusted net income dropped from $35M in Q2 last year to $16M this year, below expectations. Management said about $19M of the change reflected spending on a next-gen kidney OCS, clinical programs, and a manufacturing plant in Italy.

$TMDXHighAI 9/10

TransMedics Reports Second Quarter 2026 Financial Results

TransMedics Group (Nasdaq: TMDX) reported Q2 2026 revenue of $189.9 million, up 21% year over year, with product revenue $111.2 million and service revenue $78.8 million. Net income was $14.7 million, or $0.41 per diluted share. The company raised full-year 2026 revenue guidance (excluding PAD Aviation) to $737 million to $757 million.

$TMDXMed

TransMedics Group, Inc. (TMDX): Results of Operations and Financial Condition

TransMedics Group, Inc. (TMDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tmdx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 TransMedics Reports Second Quarter 2026 Financial Results Andover, Mass. – August 4, 2026 – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy fo

$TMDXMed

Is TransMedics Group, Inc. (TMDX) Stock Still a MedTech Growth Opportunity After Analyst Target Cut?

TheFly reported July 6 that Evercore ISI cut its TransMedics Group (TMDX) price target to $90 from $100 while keeping an Outperform rating, citing generally stable procedure volumes and capital spending trends. On the same day, TMDX said it will invest in PAD Aviation to expand its Organ Care System OCS program into Europe, aiming to improve organ access and transplant logistics.